SUDA Pharmaceuticals Ltd (SUDA), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.
Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.
SUDA can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.
SUDA has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.
Dr Sandhya Buchanan joins SUDA to lead the technology transfer, manufacturing, and quality efforts for its newly acquired invariant Natural Killer T (iNKT) cell therapy platform.
Dr Buchanan has …
SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for…
SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to announce that the Company has received firm commitments for a capital raising by placing up to 96,163,997 ordinary shares to institutional and sophi…